| Dr Erich Robert Merkle, PHD | |
|
70 N Broadway St, Room 16, Akron, OH 44308-1911 | |
| (330) 761-2830 | |
| (330) 761-3224 |
| Full Name | Dr Erich Robert Merkle |
|---|---|
| Gender | Male |
| Speciality | Psychologist - School |
| Location | 70 N Broadway St, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811264427 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TS0200X | Psychologist - School | (* (Not Available)) | Primary |
| 103T00000X | Psychologist | (* (Not Available)) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erich Robert Merkle, PHD 70 N Broadway St, Room 17, Akron, OH 44308-1911 Ph: (330) 761-2830 | Dr Erich Robert Merkle, PHD 70 N Broadway St, Room 16, Akron, OH 44308-1911 Ph: (330) 761-2830 |
News Archive
Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.
Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.
Cardiovascular diseases (CVDs) are the leading cause of death globally. Monitoring of lipid in patients with coronary heart disease (CHD) is important for decreasing the incidence of cardiovascular events.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.
MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.
› Verified 2 days ago
Mr. Terry Bendo, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1372 Delia Ave, Akron, OH 44320 Phone: 330-761-3067 | |
Jessica Feinstein, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 214 W Bowery St, Akron, OH 44308 Phone: 330-543-1000 | |
Dr. Alan Dale Gilbertson, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6525 Fax: 330-996-2943 | |
Alanna G Updegraff, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8050 Fax: 330-543-8054 | |
Elizabeth R. Holmes, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 2108 Braewick Cir, Ste 202, Akron, OH 44313 Phone: 330-920-9292 Fax: 330-920-9393 | |
James Anthony Orlando, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 37 N Broadway St, Akron, OH 44308 Phone: 330-535-8181 Fax: 330-535-9303 | |
Dr. Kevin Triemstra, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-4270 Fax: 330-543-4271 |